Adaptimmune Therapeutics PLC (ADAPY) › Cash & EquivalentsAdaptimmune Therapeutics PLC (ADAPY) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2015: $194.26M2016: $158.78M2017: $84.04M2018: $68.38M2019: $50.41M2020: $56.88M2021: $149.95M2022: $108.03M2023: $143.99M2024: $91.14M$91.14M2015Cash & Equivalents (USD)2024Fiscal YearCash & EquivalentsChange YoY2024$91.14M-36.7%2023$143.99M+33.3%2022$108.03M-28.0%2021$149.95M+163.6%2020$56.88M+12.8%2019$50.41M-26.3%2018$68.38M-18.6%2017$84.04M-47.1%2016$158.78M-18.3%2015$194.26M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share